1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Johnson & Johnson

Johnson & Johnson

JNJ.DE
Johnson & JohnsonDE flagDeutsche Börse
235.00
EUR
+0.15
- -
565.70BMarket Cap
Johnson & Johnson
JNJ.DE
(Deutsche Börse)

Recent

price

235.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
22.49
23.87
24.19
25.28
26.71
25.43
26.56
28.5
30.64
31.17
31.37
29.95
30.61
35.38
36.9
39.12
40.03
Revenue per Share
4.87
3.55
3.91
4.9
5.86
5.59
6.11
0.48
5.75
5.74
5.59
7.94
6.86
14.6
5.84
11.13
8.74
Basic EPS, GAAP
5.11
4.19
4.49
4.9
5.39
5.85
5.74
6.63
6.96
7.57
7.67
7.52
6.58
7.39
7.5
8.02
7.23
Free Cash Flow per Basic Share
2.12
2.26
2.38
2.58
2.79
2.97
3.19
3.33
3.57
3.77
3.98
4.2
4.47
4.89
4.91
5.14
5.2
Dividend per Share
29.54
30.97
32.07
32.83
36.06
38.84
42
39.11
41.07
43.22
44.45
48
50.3
65.21
1.3
1.3
1.3
Book Value per Share
8.97
8.37
4.91
8.26
7.44
8.62
7.66
-9.31
-6.88
-8.29
-10.07
-2.9
0.87
-0.81
-4.29
-7.32
-6.83
Tangible Book Value per Share
2,738
2,724
2,778
2,821
2,783
2,755
2,707
2,683
2,662
2,633
2,633
2,629
2,614
2,407
2,407
2,408
2,407
Basic Weighted Avg Shares
61,587
65,030
67,224
71,312
74,331
70,074
71,890
76,450
81,581
82,059
82,584
78,740
79,990
85,159
88,821
94,193
96,362
Sales/Revenue/Turnover
26.84
24.84
25.34
26.58
28.44
26.1
29.06
24.72
25.96
25.55
24.11
26.6
26.27
25.84
23.92
27.17
26.77
Operating Margin (%)
2,939
3,158
3,666
4,104
3,895
3,746
3,754
5,642
6,929
7,009
7,231
7,390
6,970
7,486
7,339
7,503
7,735
Depreciation Expense
13,334
9,672
10,853
13,831
16,323
15,409
16,540
1,300
15,297
15,119
14,714
20,878
17,941
35,153
14,066
26,804
21,040
Net Income, GAAP
21.32
21.75
23.67
10.6
20.62
19.73
16.48
92.64
15.01
12.75
10.81
7.18
15.44
11.53
15.71
17.73
15.64
Effective Tax Rate (%)
21.65
14.87
16.14
19.4
21.96
21.99
23.01
1.7
18.75
18.42
17.82
26.52
22.43
41.28
15.84
28.46
21.83
Profit Margin (%)
24,235
31,505
21,854
30,732
30,713
32,463
38,745
12,551
14,803
9,310
8,744
15,753
-508
7,213
5,572
1,498
1,457
Working Capital
9,156
12,969
11,489
13,328
15,122
12,857
22,442
30,675
27,684
26,494
32,635
29,985
26,886
25,881
30,651
39,438
37,527
LT Debt
56,579
57,080
64,826
74,053
69,752
71,150
70,418
60,160
59,752
59,471
63,278
74,023
76,804
68,774
71,490
81,544
81,186
Total Equity
18.73
16.76
16.37
19.45
18.5
16.3
18.39
1.43
19.24
20.33
18.81
18.66
15.64
17.75
16.84
17.37
16.03
Return on Invested Capital (%)
14.75
10.04
11.08
13.2
14.57
12.89
12.81
0.98
11.57
10.95
10.14
13.48
10.98
20.05
13.01
60.79
38.63
Return on Capital (%)
17.28
11.7
12.51
15.22
16.92
14.86
14.99
1.19
14.28
13.55
12.75
17.17
13.93
24.38
17.57
859.1
674.36
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
6,387
8,495
17,460
LT Borrowings
39,408
39,438
37,527
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,406
2,408
2,407
Market Capitalization
440,587
499,586
587,276

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
54,611
55,624
59,173
Cash, Cash Equivalents & STI
18,562
20,102
22,051
Accounts Receivable, Net
17,611
17,178
17,721
Inventories
14,146
14,191
14,583
Total Current Liabilities
50,869
54,126
57,716
Payables & Accruals
40,510
41,097
37,345
ST Debt
6,387
8,495
17,460
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.79%
5.66%
14.06%
Free Cash Flow
2.08%
-0.64%
6.94%
Net Income, GAAP
114.24%
30.87%
90.56%
Sales/Revenue/Turnover
3.06%
2.75%
6.05%
Total Cash Common Dividend
4.26%
3.41%
4.72%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
21,383
22,447
22,471
22,520
88,821
2025
21,893
23,743
23,993
24,564
94,193
2026
24,062
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.34
1.95
1.12
1.43
5.84
2025
4.57
2.3
2.14
2.12
11.13
2026
2.17
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.18
1.24
1.24
1.24
4.91
2025
1.24
1.3
1.3
1.3
5.14
2026
1.3
- -
- -
- -
- -
Similar Companies
Kyowa Kirin Co., Ltd. (4151.T)
Yung Zip Chemical Ind. Co., Ltd. (4102.TWO)
Fangzhou Inc. (6086.HK)
Ono Pharmaceutical Co., Ltd. (OPHLY)
Merck & Co., Inc. (0QAH.L)
Bayer Aktiengesellschaft (BAYN.SG)
Business
Johnson & Johnson (NYSE: JNJ; Xetra: JNJ.DE) operates as a global healthcare company focused on pharmaceuticals and medical technologies through its Innovative Medicine and MedTech segments; Innovative Medicine develops and commercializes prescription medicines addressing oncology (including solid tumors such as lung, prostate, and bladder cancers as well as hematologic malignancies; brands such as Darzalex and Imbruvica), immunology (rheumatoid arthritis, inflammatory bowel disease, psoriasis; brands such as Stelara and Tremfya), neuroscience (mood disorders, schizophrenia, neurodegenerative conditions), cardiopulmonary (thrombosis, pulmonary arterial hypertension), and specialty ophthalmology; MedTech provides interventional cardiology and electrophysiology devices, orthopaedics implants and systems (joint reconstruction, trauma, extremities, craniomaxillofacial, spinal surgery, sports medicine; including VELYS digital surgery portfolio), surgery products, and vision care solutions. The company maintains manufacturing facilities and R&D operations worldwide, targeting patients, healthcare providers, and institutions across more than 100 countries. Founded in 1886 by brothers Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson, Johnson & Johnson maintains its world headquarters in New Brunswick, New Jersey. In recent developments, Johnson & Johnson completed the spin-off of its consumer health business as Kenvue Inc. in 2023, allowing concentration on Innovative Medicine and MedTech; the company announced over $55 billion in U.S. investments through 2029 for advanced manufacturing facilities (including a new biologics plant in Wilson, North Carolina), R&D in oncology, neuroscience, immunology, cardiovascular disease, and robotic surgery, and technology enhancements, representing a 25% increase from prior levels; key 2024-2025 acquisitions include Shockwave Medical ($13.1 billion) for cardiovascular intravascular lithotripsy, Intra-Cellular Therapies ($15 billion) for neuroscience, Halda Therapeutics ($3.05 billion) for novel cancer therapies, Proteologix ($850 million) for immunology, and Ambrx ($2 billion) for bioconjugates, with ongoing talks for Protagonist Therapeutics to expand oncology and immunology portfolios.